On 10 December 2025, Zydus Lifesciences announced the Indian launch of Zyrifa™ (denosumab 120mg SC), biosimilar to Amgen’s Xgeva® (denosumab).
The launch of Zydus’ denosumab biosimilar in India follows a flurry of European denosumab biosimilar launches on 1-2 December, including Sandoz’s Jubbonti® and Wyost®, Fresenius Kabi’s Conexxence® and Bomyntra®, Zentiva’s Zadenvi®, Accord Healtcare’s Osvyrti® and Jubereq® and Samsung Bioepis’ Xbryk™ (available from December 2025).
Denosumab biosimilars launched in the US include Sandoz’s Jubbonti® and Wyost® (June 2025), Celltrion’s Stoboclo® and Osenvelt® (July 2025), Fresenius Kabi’s Conexxence® and Bomyntra® (July 2025), and Biocon’s Bosaya™ and Aukelso™ (October 2025).
In August 2025, it was reported that India’s Central Drugs Control Organisation (CDSCO) had reviewed and accepted without objection a final Clinical Study Report submitted by Intas Pharmaceuticals for its proposed denosumab biosimilar.